The University of British Columbia
UBC - A Place of Mind
The University of British Columbia
Faculty of Medicine
  • Home
  • Admissions
  • About
    • Strategic Plan
    • Vision & Values
    • Land Acknowledgement
    • Indigenous Health
    • Leadership
    • Academic & Research Units
    • Campuses
    • Facts & Figures
    • Careers
    • Contact
  • News
    • Feature Stories
    • Pathways Magazine
    • The Next Big Question
  • Education
    • Programs
    • Faculty Development
    • Health Education Scholarship
    • Continuing Professional Development
  • Research
    • Priority Areas
    • Canada’s Immuno-Engineering and Biomanufacturing Hub
    • COVID-19 Clinical Research Coordination Initiative
    • Academy of Translational Medicine
    • Edwin S.H. Leong Centre for Healthy Aging
    • Centres & Institutes
    • National Prizes
  • Giving
    • Impact of Giving
    • By the Numbers
    • Ways to Give
    • Webinar Series
    • Contact Us
  • Prospective Students
  • Current Learners
    • Policies & Procedures
    • Respectful Environments, Equity, Diversity & Inclusion
    • Mistreatment Help
    • MD & Undergrad Research
    • Summer Student Research Program
    • Multidisciplinary Research Program in Medicine
    • Grad & Postdoc Education
  • Faculty & Staff
  • Clinical Faculty
    • Becoming Clinical Faculty
    • Appointment Policy & Compensation Terms
    • Teaching Tracking & Payment System
    • Services & Perks
    • Career Development
    • Awards
    • Celebrating Clinical Faculty
    • Advisory Council
    • Contacts
  • Alumni
» Home » News » New drug target found for cystic fibrosis lung disease

Contact

Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421

New drug target found for cystic fibrosis lung disease

By bkladko | November 8, 2012

A team led by Stuart Turvey, an Associate Professor of Pediatrics, has discovered the cellular pathway that causes lung‐damaging inflammation in cystic fibrosis (CF), and found that reducing the pathway’s activity also decreases inflammation.

The finding offers a potential new drug target for treating this form of lung disease, which is a major cause of illness and death for people with CF.

Stuart Turvey

“Developing new drugs that target lung inflammation would be a big step forward,” says Dr. Turvey, the director of clinical research and senior clinician scientist at the Child & Family Research Institute (CFRI) and a pediatric immunologist at BC Children’s Hospital.

The research, published online in the Journal of Immunology, compared the immune response of normal lung cells with that of CF lung cells after exposing both types of cells to bacteria in the lab. In healthy cells, exposure to bacteria triggers the cell to secrete special molecules that attract immune cells to fight the infection. In CF lung cells, the researchers discovered that a series of molecular events called the unfolded protein response is more highly activated. It causes the CF lung cells to secrete more molecules that attract an excessive amount of immune cells, which leads to increased inflammation.

They also found that treating the CF cells with a special chemical normalized the unfolded protein response and stabilized the cells’ immune response.

CF is the most common genetic disease affecting young Canadians, affecting one in every 3,600 children born in Canada. A build‐up of mucus in the lungs causes people with CF to be susceptible to bacterial lung infections, which trigger inflammation and swelling. Over time, the recurring cycle of infections and inflammation damages the lungs and can lead to the need for lung transplantation. The only treatments for lung inflammation are steroids and anti‐inflammatory medications, which can have significant side effects.

The researchers are planning further study to validate these findings in a larger number of lung cell samples from people with CF.

This discovery, resulting from a collaboration among Vancouver investigators and trainees based at CFRI, BC Children’s Hospital, UBC and the Providence Heart + Lung Institute at St. Paul’s Hospital was supported by Cystic Fibrosis Canada and the Michael Smith Foundation for Health Research.

Contact Information

Communications
UBC Faculty of Medicine
Email: communications.med@ubc.ca
Office: 604.822.2421
Faculty of Medicine
317 - 2194 Health Sciences Mall
Vancouver, BC Canada V6T 1Z3
Tel 604 822 2421
Website www.med.ubc.ca
Find us on
    
Back to top
The University of British Columbia
  • Emergency Procedures |
  • Terms of Use |
  • Copyright |
  • Accessibility